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Abstract
Background: Influenza viruses cause serious infections that can be prevented or treated using vaccines or antiviral agents,
respectively. While vaccines are effective, they have a number of limitations, and influenza strains resistant to currently
available anti-influenza drugs are increasingly isolated. This necessitates the exploration of novel anti-influenza therapies.
Methodology/Principal Findings: We investigated the potential of aurintricarboxylic acid (ATA), a potent inhibitor of
nucleic acid processing enzymes, to protect Madin-Darby canine kidney cells from influenza infection. We found, by neutral
red assay, that ATA was protective, and by RT-PCR and ELISA, respectively, confirmed that ATA reduced viral replication and
release. Furthermore, while pre-treating cells with ATA failed to inhibit viral replication, pre-incubation of virus with ATA
effectively reduced viral titers, suggesting that ATA may elicit its inhibitory effects by directly interacting with the virus.
Electron microscopy revealed that ATA induced viral aggregation at the cell surface, prompting us to determine if ATA could
inhibit neuraminidase. ATA was found to compromise the activities of virus-derived and recombinant neuraminidase.
Moreover, an oseltamivir-resistant H1N1 strain with H274Y was also found to be sensitive to ATA. Finally, we observed
additive protective value when infected cells were simultaneously treated with ATA and amantadine hydrochloride, an anti-
influenza drug that inhibits M2-ion channels of influenza A virus.
Conclusions/Significance: Collectively, these data suggest that ATA is a potent anti-influenza agent by directly inhibiting the
neuraminidase and could be a more effective antiviral compound when used in combination with amantadine hydrochloride.
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Introduction
Influenza viruses cause a highly contagious respiratory tract
infection. The frequent mutations of influenza genes, particularly
those encoding surface hemagglutinin (HA) and neuraminidase
(NA) proteins, allow the virus to evade the host immune system.
This gives rise to new infectious strains responsible for annual
epidemics associated with significant morbidity and mortality
[1,2]. The recent infections of humans with the highly pathogenic
avian H5N1 [3] and swine-origin H1N1 [4] influenza viruses
reinforce the notion that the emergence of novel virus strains is
unpredictable and capable of threatening the worldwide popula-
tion [5]. Given the magnitude of a flu pandemic as a threat to the
global population, it is crucial to have as many prevention and
treatment options as possible.
Vaccines, either inactivated or live attenuated viruses, offer the
best protection against influenza infection by inducing neutralizing
antibodies against HA and NA antigens of specific influenza
strains [6]. However, current vaccines are not ideal because they
must be developed and validated annually [6], have lengthy
manufacturing and distribution times [7] and short shelf lives [8].
Most importantly, any failure to accurately anticipate the
circulating strain results in reduced efficacy or no protection by
these vaccines [1,9–12]. These drawbacks, associated with inter-
pandemic vaccines, would be drastically exacerbated in the event
of a future pandemic [8,13]. It is therefore crucial to investigate
novel therapeutic and preventive anti-influenza agents.
Presently, only two classes of antiviral agents have been
developed and approved for prophylaxis and treatment of seasonal
influenza infection [5,14]. The first class blocks the influenza M2
protein, which forms hydrogen ion channels required for the
efficient uncoating of incoming viruses [5,14]. The second class
inhibits influenza NA, which is required for efficient release of viral
particles from the infected cell [5,14]. However, resistance to both
M2 blockers and NA inhibitors has been reported to be extensive
[5,14–16].
Aurintricarboxylic acid (ATA) is a polyaromatic carboxylic acid
derivative [17] that inhibits nucleases [18] and nucleic acid
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replication of human immunodeficiency [19,20] and vesicular
stomatitis [17] viruses. More recently, we found that ATA could
inhibit the severe acute respiratory syndrome-associated corona-
virus (SARS-CoV) [21] and vaccinia virus [22]. Here, we report
that ATA can substantially inhibit the replication of several strains
of influenza A viruses and one-type B virus in tissue cultures with
moderate cytotoxicity. We further investigated the combinational
effects of ATA and amantadine hydrochloride, an M2 blocker, on
the replication of influenza viruses. Finally, we found that ATA
inhibits influenza neuraminidase, possibly elucidating its anti-
influenza mechanism of action.
Materials and Methods
Cell Culture and Viruses
Madin-Darby canine kidney (MDCK) cells (ATCC: CCL-34)
were obtained from the American Type Culture Collection
(Manassas, VA, USA) and were grown in modified minimum
essential medium (modified MEM) containing Earle’s balanced
salts and supplemented with 2 mM L-glutamine, 1.5 g/l sodium
bicarbonate (pH 7.2), 0.1 mM non-essential amino acids, 1.0 mM
sodium pyruvate, 10% heat-inactivated fetal bovine serum (FBS),
100 U/ml penicillin and 100 mg/ml streptomycin (Invitrogen,
Carlsbad, CA) in a humidified atmosphere of 5% CO2. All viruses
were amplified and titrated in MDCK cells and stored at 280uC
until use. Influenza A strains A/Puerto Rico/8/34 (H1N1)
(hereafter referred to as PR8), A/New Caledonia/20/99 (H1N1)
(hereafter referred to as NC), and A/New York/55/01 (H3N2)
(hereafter referred to as NY) were kindly provided by Dr. Jim
Robertson at the National Institute for Biological Standards and
Control (Potters Bar, UK). The oseltamivir-resistant influenza
virus A/WSN/33 with the substitution of H274Y was made by
reverse genetics and provided by Dr. Guy Boivin (Laval
University, Quebec City, QC, Canada) and is hereafter referred
to as H274Y in this paper. The parental virus influenza A/WSN/
33 (H1N1) virus (hereafter referred to as WSN) was obtained from
Dr. Earl Brown at University of Ottawa, Ottawa, ON, Canada.
Influenza B/Singapore/222/97 virus (hereafter referred to as B)
was provided by Dr. Kathryn Wright (Biochemistry, Microbiology
and Immunology Department, University of Ottawa, Canada).
Confluent MDCK monolayers in 6 or 24-well plates were washed
twice with PBS and incubated with viruses at a multiplicity of
infection (MOI) of 0.001 in MEM for 2 h at 37uC. After viral
adsorption, media was removed, cells were washed twice with PBS
and incubated with post-adsorption medium [MEM with 2 mM
L-glutamine and Earle’s balanced salts supplemented with 100 U/
ml penicillin and 100 mg/ml streptomycin, 25 mM HEPES buffer
(pH 7.2), 0.1 mM non-essential amino acids, 1.0 mM sodium
pyruvate, 2 mg/ml L-1-(tosylamido-2-phenyl) ethyl chloromethyl
ketone (TPCK)-treated trypsin (Invitrogen, Carlsbad, CA)]. Plates
were incubated for 48 h at 37uC, 5% CO2.
Compounds
Aurintricarboxylic acid (ATA), amantadine hydrochloride (AH),
and N-acetyl-2,3-dehydro-2-deoxyneuraminic acid (NAA) were
from Sigma (St. Louis, MO, USA). Stock solutions of each drug
were prepared immediately before use in dimethyl sulfoxide
(DMSO) and filtered using a 0.22 nm filter.
Neutral Red Assay
Neutral red is a vital dye that is incorporated into the vacuoles
of viable cells, can be detected spectrophotometrically and is used
to determine cell viability. The in vitro efficacy and toxicity of
antiviral compounds have previously been determined by
measuring the uptake of neutral red [23–25], therefore a neutral
red assay kit (Sigma, St. Louis, USA) was used to assess the
cytotoxicity and antiviral potential of ATA according to
manufacturer’s instructions. To determine ATA cytotoxicity,
confluent MDCK monolayers in 24-well plates were washed
twice with PBS then exposed to ATA in 1 ml post-adsorption
medium for 48 h at 37uC, 5% CO2. To determine inhibitory
potential of ATA alone or in combination with AH, inoculums
were aspirated following viral adsorption, cells were washed twice
with PBS, then incubated in 1 ml post-adsorption medium
containing ATA and/or AH for 48 h at 37uC, 5% CO2. DMSO
concentration was the same in all treatments. After 48 h, neutral
red dye was added to the medium in each well at a concentration
of 0.033% and incubated for 2 h at 37uC. The medium was then
removed, and cells were fixed by rinsing with 0.1% CaCl2 in 0.5%
formaldehyde. The incorporated dye was solubilized in 1 ml of
1% acetic acid in 50% ethanol. Cells were incubated at room
temperature for 10 min with gentle agitation and the absorbance
was measured at 540 nm with a Synergy
TM 2 Multi-Mode
Microplate Reader. MDCK cells were also evaluated by
microscopic examination for cytopathic effect (CPE). Results for
ATA cytotoxicity were presented as percentage of absorbance of
ATA-treated cells relative to that from untreated controls. ATA
and/or AH protection results were expressed as percentage of
absorbance of treated or untreated infected cells relative to that
from untreated, uninfected controls. The concentration of drug
required to inhibit 50% of the CPE induced by PR8 (EC50) was
determined.
Reverse Transcription-PCR
Total RNA was extracted from cells 48 h following infection
with influenza PR8 and treatment with ATA using an RNeasy
mini kit (Qiagen Inc. Valencia, CA). Extracted RNA was treated
with DNAse I (Ambion Inc., Streetsville, Ontario, Canada) and
single step reverse transcription-PCR was performed using a Titan
One Tube RT-PCR kit (Roche Applied Science, 68298
Mannheim, Germany) according to manufacturer’s instructions.
Influenza PR8 nucleoprotein RNA was amplified from 200 ng
RNA in a total reaction volume of 50 ml using the forward and
reverse primers 59-ACTCACATGATGATCTGG-39 and 59-
CTGCATTGTCTCCGAAGA-39, respectively. Reverse tran-
scription was performed at 50uC for 30 min. After an initial
denaturation at 94uC for 2 min, two amplification steps were
performed. The first step consisted of 10 cycles of denaturation at
94uC for 30 sec, annealing at 58uC for 30 sec and elongation at
68uC for 45 sec. The second step consisted of 18 cycles under the
same cycling conditions, with 5 sec added to the elongation step in
each cycle. After a final extension at 68uC for 7 min, 20 ml of the
RT-PCR product was loaded on an 1% agarose gel and visualized
by SYBR Green staining and UV exposure.
Enzyme Linked Immunosorbent Assay (ELISA)
Extracellular influenza A antigens were detected in cell culture
supernatants using a commercial ELISA kit (Takara Bio Inc.,
Otsu, Shiga, Japan). Culture media were removed 48 h after cells
were infected with virus and treated with ATA, AH or both.
Supernatants were clarified by centrifugation at 50006g for
5 min. Samples, positive control and standards diluted in diluent/
lysis buffer were added to individual wells (100 ml/well), and
incubated at 37uC for 1 h with immobilized monoclonal antibody
directed against influenza A nucleoprotein (NP), then were washed
three times with PBS containing 0.1% Tween-20. Samples were
incubated with biotinylated rabbit polyclonal anti-influenza virus
ATA Inhibits Influenza Virus
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phenylenediamine dihydrochloride conjugates were added to wells
and the plate incubated for 30 min at 37uC. Wells were washed
four times and incubated with the substrate solution consisting of
hydrogen peroxide and tetramethylbenzidine at room temperature
for 15 min. The reaction was stopped by the addition of 1 N
H2SO4 prior to absorbance reading at 450 nm using a Synergy
TM
2 Multi-Mode Microplate Reader. Viral abundance was calculat-
ed as hemagglutination (HA) units from a standard curve using a
positive control with known HA content. One HA unit is equal to
the quantity of virus required to completely aggregate erythrocytes
in an HA assay (100 ml of 0.25% v/v). The commercial ELISA kit
has certain limitations as it employs the anti-nucleoprotein as the
capture antibodies coated on the plates and anti-influenza viral
proteins (total influenza viral proteins including hemagglutinins) as
the detecting antibodies in solution for sandwich ELISA. Because
hemagglutinins vary from strain to strain in terms of amino acid
sequences or the ratio of viral proteins, one cannot directly
compare the HA units between two different strains. Therefore,
we present the results as percentage of HA units from treated
infected samples relative to that from untreated infected control
for the same strain.
Cell-Associated and Extracellular Virus Yield Reduction
Assay
Confluent cells in 6 well plates were washed twice with PBS and
inoculated with 1 ml MEM containing PR8 for 2 h at 37 uC.
Inoculums were aspirated, cells were washed twice with PBS and
treated with 1% DMSO, 100 mg/ml ATA, 100 mg/ml AH or
100 mg/ml NAA for 48 h at 37uC. Cells were scraped off wells and
collected by centrifugation at 16006g for 5 min. Supernatants
were transferred to a new tube, then cells were lysed by 2 cycles of
freezing and thawing. Supernatants and lysates were subjected to
plaque assay as described previously [26] to determine the
extracellular and cell-associated virus titer yield upon ATA
treatment. Confluent cell monolayers in 6 well plates were
incubated with 1 ml of supernatant or lysate at 37uC for 2 h.
The inoculum was removed, cells were washed with PBS and
overlaid with the maintenance MEM medium containing 0.8%
agarose, 0.2% BSA, 2 mM L-glutamine, 1.5 g/l sodium bicar-
bonate (pH 7.2), 0.1 mM non-essential amino acids, 1.0 mM
sodium pyruvate, 100 U/ml penicillin, 100 mg/ml streptomycin
and 2 mg/ml TPCK-treated trypsin. After incubation for 3 days at
37uC in a humidified atmosphere of 5% CO2, cells were either
stained with 0.01% neutral red directly or fixed with 10%
formaldehyde, followed by staining with 0.5% crystal violet for
plaque counting.
Direct Inactivation of the Viruses
PR8, NC, NY, WSN, H274Y and influenza B viruses, at a
concentration of ,100 plaque forming units (pfu), were incubated
with ATA at 37uC for 30 min. The virus-ATA mixture was
transferred to confluent cell monolayers in 6-well plates, incubated
at 37uC for 2 h and subjected to plaque assay as described
previously [26].
Electron Microscopy
Confluent cells in 6 well plates were inoculated with PR8 virus
for 2 h at 37uC, then treated with DMSO, 100 mg/ml ATA,
100 mg/ml AH in post-adsorption medium for 24 h at 37uC. Cells
were scraped off wells and centrifuged at 16006g for 5 min.
Medium was discarded and cells were incubated with ice-cold
fixative (2.5% glutaraldehyde in 0.2 M cacodylate buffer, pH 7.4)
for 50 min, with gentle agitation. Cells were pelleted by
centrifugation at 20,0006g for 2 min at room temperature. Cell
pellets were re-suspended in 0.5 ml fixative then rinsed in 0.5 M
cacodylate buffer twice for 10 min and post-fixed with 2% osmium
tetroxide for 2 h. The fixed cells were washed with water twice for
10 min, dehydrated with increasing concentrations of ethanol
from 50 to 100% and embedded in spurr resin. Thin (70–80 nm)
sections were cut on an ultramicrotome and counter stained with
uranyl acetate and lead citrate. The sections were viewed and
photographed on a JEOL 1010 transmission electron microscope.
Cell-Free Neuraminidase Inhibition Assay
The NA-StarH Influenza Neuraminidase Inhibitor Resistance
Detection Kit (Applied Biosystems, Foster City, CA, USA) was
used to measure the inhibition of NA activity as described
previously [27,28]. Briefly, serial dilutions of ATA, AH and NAA
ranging from 2000 mg/ml to 0.002 mg/ml were prepared in NA-
Star assay buffer, i.e. 26 mM MES (2-[N-Morpholino] ethane-
sulfonic acid), pH 6.0, 4 mM CaCl2, such that dilutions were
double the final concentration. Twenty-five ml of each drug
dilution was combined with 25 ml diluted viruses (PR8, NC, NY,
WSN, H274Y and B) or recombinant NA proteins [recombinant
N1 protein (influenza A/Beijing/262/95) and N4 protein
(influenza A/Gray Teal/Aus/2/79) (Protein Sciences Corpora-
tion, Meriden, CT, USA)] in NA-Star assay buffer. Mixtures were
incubated at 37uC with gentle agitation for 30 min to allow
interaction between drug and virus or recombinant NA protein.
Ten ml of NA-Star substrate diluted in assay buffer to a final
concentration of 10 mM was added to each mixture in an opaque,
solid-white 96-well plate. The reactions were incubated at 37uC
for 30 min with gentle agitation, then 60 ml of NA-Star accelerator
was added to each well and a chemiluminescent signal was
measured at a rate of 1 sec/well in a Synergy
TM 2 Multi-Mode
Microplate Reader. Curves were constructed by plotting the
percentage of NA activity (chemiluminescent signal) in the
presence of inhibitors relative to the activity of controls (NA
without inhibitors) against the concentration of inhibitors and used
to determine the drug concentration required to reduce NA
activity to 50% of control NA activity (IC50).
Data Analysis
All data were expressed as means 6 standard deviation. NA
inhibition assay and IC50 calculations were determined using
Figure 1. ATA protects MDCK cells from infection with
influenza A strains PR8, NY or NC. MDCK cells infected with
influenza A viruses (MOI 0.001) were treated with ATA for 48 h. Cell
viability was assessed by neutral red assay. The columns represent the
means of triplicates and error bars represent standard deviations.
*=corrected p-value ,0.05.
doi:10.1371/journal.pone.0008350.g001
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analysis was conducted using either one-way or two-way ANOVA
when appropriate. To adjust for multiple comparisons, Bonferroni
comparison post test was used. P value of ,0.05 was regarded as
statistically significant.
Results
ATA Protects MDCK Cells from Influenza A Strains
We and others have reported that ATA can inhibit certain RNA
viruses; therefore, we postulated that ATA may also inhibit the
replication of influenza viruses. To evaluate the ability of ATA to
protect MDCK cells from influenza infection, cells inoculated with
different influenza A viral strains were incubated in the presence
or absence of ATA (50 or 100 mg/ml) for 2 days. Microscopic
examination revealed a drastic reduction of influenza-induced
CPE following treatment with ATA (data not shown). The viability
of MDCK cells infected with influenza A viruses and incubated in
the presence or absence of ATA was then assayed by
incorporation of neutral red dye. Infected cells treated with
ATA had increased neutral red uptake (Fig. 1), confirming that
ATA significantly protected MDCK cells from influenza infection
(p,0.0001). ATA concentration that caused 50% cytotoxicity
(CC50) in MDCK cells was determined by assaying neutral red
uptake and was found to be 577 mg/ml (Fig. 2A). As shown in
Fig. 2B, ATA prevented PR8 infection of MDCK cells in a dose-
dependent manner with a minimum effective dose of 6.5 mg/ml
required to protect 50% of cells (EC50). Therefore, the
therapeutic/selective index (SI) which refers to the ratio of the
amount of ATA exerting its therapeutic effect to the amount that
causes toxicity in MDCK cells is 88.8.
To examine the prophylactic potential of ATA against influenza
A infection, MDCK cells were exposed to ATA 24 h prior to viral
infection. The cell viability was then assessed by measuring neutral
red uptake. We found that pre-exposing MDCK cells to ATA 24 h
prior to infection did not protect cells from virus-induced CPE
(data not shown). Collectively, these data suggest that ATA is a
potent anti-influenza agent with relatively low toxicity in tissue
culture, as demonstrated by the SI value of 88.8.
ATA Inhibits Replication of Influenza A and B Viruses
To examine whether the protective effect of ATA is due to
inhibition of viral replication, the level of influenza nucleoprotein
RNA isolated from PR8-infected MDCK cells was determined by
reverse-transcription PCR. Cells infected with PR8 had low levels
of b -actin RNA (Fig. 3), most likely due to cell death. However,
the level of b-actin RNA remained relatively constant upon
exposure to increasing ATA concentrations. Treatment with ATA
Figure 2. Determination of the selective index of ATA in MDCK cells. (A) Cytotoxicity of ATA in MDCK cells. MDCK cells were treated with
ATA for 48 h at the indicated ATA concentrations (mg/ml). Cell viability was determined by neutral red assay by measuring the absorbance at 540 nm.
Samples were tested in quadruplicate and showed as means and standard deviations (error bars). (B) Inhibition of influenza A PR8 infection in MDCK
cells by ATA is concentration-dependent. MDCK cells were infected with influenza A PR8 virus (MOI 0.001) and treated with ATA at increasing
concentrations for 48 h. Cell viability was determined by neutral red assay by measuring the absorbance at 540 nm. Samples were tested in duplicate
and showed as means and standard deviations (error bars).
doi:10.1371/journal.pone.0008350.g002
Figure 3. ATA reduces the level of influenza NP RNA detectable
in MDCK cells. MDCK cells were infected with influenza A PR8 virus
and treated with the indicated concentrations of ATA for 24 h. Total
RNA was extracted and reverse-transcription PCR was performed to
determine NP and b-actin RNA levels.
doi:10.1371/journal.pone.0008350.g003
Figure 4. ATA reduces viral release from infected MDCK cells
into the media. MDCK cells were inoculated with influenza A viruses
(MOI 0.001), then treated with ATA for 48 h. Media were collected and
released viruses were quantified by ELISA. The columns represent the
means of triplicates and error bars represent standard deviations.
*=corrected p-value ,0.05.
doi:10.1371/journal.pone.0008350.g004
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untreated cells, suggesting that ATA protects MDCK cells by
decreasing viral replication.
To determine if ATA treatment also reduces the level of
influenza viruses released into the medium, supernatants from
ATA-treated infected cell cultures were subjected to the analyses
of viral proteins by ELISA. As shown in Fig. 4, treatment of cells
with ATA dramatically reduced virus yield (p,0.0001). Doses of
50 mg/ml and 100 mg/ml of ATA reduced the abundance of PR8
by 93% and 95%, NC by 86% and 94%, and NY by only 72%
and 81%, respectively. There is no statistically significant
difference between the two H1N1 viruses (PR8 and NC), yet the
H3N2 virus was slightly more resistant to the ATA treatment (see
below for additional discussion).
Since an ELISA measures both infectious and non-infectious
particles, we determined whether ATA treatment specifically
reduces the abundance of infectious particles. Cells were infected
with PR8, then exposed to ATA or other previously established
anti-influenza agents, AH, an M2 blocker or NAA, a neuramin-
idase inhibitor. Virus titres, of both the cell lysate and
supernatant fraction, were determined by plaque assay. ATA
treatment significantly reduced both the cell-associated and
extracellular virus yields when compared to either AH or NAA
(Table 1). Moreover, when ATA was included in the mainte-
nance media in a plaque reduction assay with cells infected with
either influenza A or B viruses, it reduced both the number and
size of plaques (data not shown). Taken together, these data
s u g g e s tt h a tA T Ai sap o t e n ti n h i b i t o ro fi n f l u e n z aAa n dB
viruses.
The Inhibition of Influenza Viruses by ATA and AH Is
Additive
Upon demonstrating that ATA protects MDCK cells from
influenza infection by reducing viral replication and release, we
sought to investigate the mechanism underlying the anti-influenza
activities of ATA. The protection of influenza-infected MDCK
cells should be enhanced by simultaneous treatment with two
antivirals acting via different mechanisms. Therefore, MDCK cells
infected with influenza were treated concomitantly with ATA and
an agent with a known antiviral mechanism. As shown in Fig. 5,
the cytopathic effect induced by influenza A viruses in MDCK
cells was reduced significantly by concomitant treatment with
ATA and AH, compared to either treatment alone. The protective
effects of combined ATA and AH treatment were further
confirmed by quantitative detection of influenza A viruses present
in the culture supernatants by ELISA (Fig. 6). Notably, co-
treatment with ATA and AH virtually abolished H1N1 and H3N2
virus production in the media. Since AH effects its anti-influenza
properties by targeting the viral M2 protein to prevent efficient
uncoating of incoming viral particles, we concluded that inhibition
of influenza replication and release by ATA is mediated by a
distinct mechanism.
ATA Inhibits Neuraminidase Activities of Influenza A and
B Viruses
To begin to elucidate how ATA protects cells from influenza
infection, we investigated whether ATA elicits its inhibitory actions
directly on the virus. In previous experiments, the consequences of
ATA were examined after viral infection. To determine if ATA
inhibits influenza viruses directly, MDCK cells were infected with
viruses that had been pre-incubated with ATA, and then subjected
to plaque assay. As shown in Fig. 7, pre-incubation of influenza A
and B viruses with ATA reduced the number of plaques and
protected cells, suggesting that ATA can inactivate viral proteins
directly.
To gain insight into how ATA directly inhibits influenza virus,
MDCK cells infected with PR8 and treated with ATA or AH
were examined by election microscopy. Compared to untreated
PR8-infected cells, or those incubated with AH, ATA treatment
was found to induce viral aggregati o no nt h ec e l ls u r f a c e( F i g .8 ) .
T h e s ef i n d i n g sa r es i m i l a rt op r e v i o u so b s e r v a t i o n sb yi n v e s t i g a -



















Confluent MDCK cells in 6 well plates were infected with 0.001 MOI of influenza
A PR8 virus and incubated for 48 h with 100 mg/ml of AH, ATA, NAA or DMSO
alone. Culture media and cell lysates were collected and viral titers were
determined by plaque assay.
doi:10.1371/journal.pone.0008350.t001
Figure 5. ATA and AH protect MDCK cells from influenza A infection. Uninfected MDCK cells, or MDCK cells infected with influenza A strains
were treated with either ATA alone, AH alone, or in combinations at concentrations indicated. (A) MDCK cells infected with influenza A PR8 virus; (B)
MDCK cells infected with influenza A NC virus; (C) MDCK cells infected with influenza A NY virus. Protection of cells from infection was determined by
NR dye uptake. Cell viability was determined by measuring the absorbance at 540 nm. The columns represent the means of triplicates and error bars
represent standard deviations. *=corrected p-value ,0.05. Not all statistically significant differences are shown.
doi:10.1371/journal.pone.0008350.g005
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[29,30]. In these studies, NA was believed to prevent aggregation
of progeny viruses on the surfaces of infected cells [29,31,32].
Therefore, we postulated that ATA elicits viral aggregation by
inhibiting the enzymatic activity of NA. To address this question,
we tested the effect of ATA on NA activity and compared it to the
effect of NAA, a known NA inhibitor [30]. As expected, NAA
inhibited NA activity with very low IC50 values, while AH
showed no inhibition (data not shown). We found ATA inhibited
NA activity in a concentration-dependent manner in all viruses,
with no marked differences among them. As shown in Fig. 9A,
ATA inhibited NA activity from influenza PR8, NC, NY and B
viruses with IC50so f7 . 2mg/ml, 16.6 mg/ml, 16.4 mg/ml and
6.3 mg/ml, respectively. In addition, ATA significantly inhibited
the enzymatic activities of two recombinant NA proteins, N1 and
N4 (Fig. 9B) with IC50so f0 . 5 2 mg/ml and 1.0 mg/ml,
respectively.
ATA Inhibits Wild-Type and Oseltamivir-Resistant Viruses
Next we tested the effect of ATA on a common oseltamivir-
resistant viral strain, i.e. WSN (H1N1) virus with the substitution
at H274Y, in comparison with the parental wild-type WSN H1N1
virus [33]. As shown in Fig. 10A and 10B, ATA inhibited
replication of both WSN and H274Y viruses in a dose-responsive
fashion. The IC50 values obtained for ATA inhibition of WSN and
H274Y viruses were 2 mg/ml and 18 mg/ml, respectively
(Fig. 10B). Although the H274Y mutation significantly increased
ATA IC50 by 9-folds as compared to the wild-type virus, ATA
remains a potent inhibitor of both wild-type WSN and H274Y
oseltamivir-resistant WSN when compared to the 754-fold
increase in IC50 of oseltamivir in inhibiting the H274Y mutant
[33].
Discussion
The influenza virus is highly contagious and results in significant
morbidity and mortality [2,34]. While mass vaccination of a
susceptible population is the best approach to prevent influenza
infections, propensity for mutation and gene reassortment can
result in an occasional emergence of novel and unpredicted
influenza virus strains. This can give rise to a global influenza
pandemic, such as the current triple reassortant swine-origin
H1N1 influenza virus [4,35]. Since considerable time is required
to develop and distribute vaccines, novel influenza strains can
rapidly spread globally before a vaccine is available for mass
immunization. Given the potential for widespread influenza
infection, it is crucial to understand and improve treatments for
this disease.
Antiviral drugs currently in use (such as the M2 blockers
amantadine and rimantidine and NA inhibitors oseltamivir and
zanamivir) can reduce the duration of flu symptoms. However, a
single mutation can render influenza viruses resistant to antiviral
drugs such as M2 blockers or NA inhibitors [36] and drug-
resistant influenza strains have been isolated from patients
receiving antiviral treatment [15,16,37–39]. These findings
necessitate the exploration of novel anti-influenza agents. We
[21,22] and others [17,19,20] have observed that ATA can inhibit
a variety of viruses. These observations prompted us to determine
the effects of ATA on the replication of influenza virus. In this
Figure 6. ATA and AH decrease the abundance of viruses released by infected MDCK cells. Viruses in culture supernatants were detected
by ELISA 48 h following treatment with ATA, AH or both compounds. (A) MDCK cells infected with influenza A PR8 virus; (B) MDCK cells infected with
influenza A NC virus; (C) MDCK cells infected with influenza A NY virus. The columns represent the means of 6 replicates and error bars represent
standard deviations. *=corrected p-value ,0.05. Not all statistically significant differences are shown.
doi:10.1371/journal.pone.0008350.g006
Figure 7. ATA inactivates influenza A and B viruses. Influenza
PR8, NC, NY and B viruses were pre-incubated with ATA (0, 50, 100 mg/
ml) for 30 min, then the virus-ATA mixture was transferred to confluent
cell monolayers in 6-well plates, incubated at 37uC for 2 h and
subjected to plaque assay.
doi:10.1371/journal.pone.0008350.g007
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protects MDCK cells from infection with H1N1 and H3N2
influenza A strains. Specifically, RT-PCR and ELISA analyses
indicated that ATA treatment both reduced the intracellular
accumulation of viral genomes and the release of influenza viruses
into the media. The magnitude of inhibition, as determined by the
Figure 8. Influenza PR8 virus forms aggregates upon ATA treatment. MDCK cells were infected with influenza A PR8 virus and exposed to
DMSO, AH or ATA, then processed for electron microscopy. (A and B) Low and high magnification view, respectively, of MDCK cells infected with
influenza A PR8 virus in the presence of DMSO only. (C and D) Low and high magnification view, respectively, of MDCK cells infected with influenza A
PR8 virus in the presence of AH. (E and F) Low and high magnification view, respectively, of MDCK cells infected with influenza A PR8 virus in the
presence of ATA.
doi:10.1371/journal.pone.0008350.g008
Figure 9. ATA inhibits NA enzymatic activity. ATA inhibits enzymatic activity of NA (A) derived from PR8, NC, NY and B viruses, (B) recombinant
N1 and N4 proteins. Viruses or recombinant proteins were incubated with increasing concentrations of ATA and NA enzymatic activity was
determined by a chemiluminescent assay. Samples were tested in quadruplicates and presented as means and standard deviations (error bars).
doi:10.1371/journal.pone.0008350.g009
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logs compared to 1–2 log reduction by either NAA or AH
(Table 1).
Although ATA has been reported to have antiviral activity
against human immunodeficiency virus [19,20], vesicular
stomatitis virus [17], SARS-CoV [21] and vaccinia virus [22],
the mechanism by which ATA inhibits such a diverse group of
viruses has remained largely undefined. Various biological
activities have been ascribed to ATA. It has been characterized
as an inhibitor of nucleic acid processing enzymes [19],
nucleases [18], kinase [40] and the JAK-STAT pathway [41],
and has been described as an anti-apoptotic factor [40,42] and
insulin-like growth factor [43]. The variety of cellular activities
associated with ATA has complicated the elucidation of its
antiviral mechanism. While it was previouslyproposed that ATA
inhibits influenza viruses by compromising viral RNA-depen-
dent polymerase [44], we present evidence suggesting that the
antiviral activities of ATA could be attributed to the inhibition of
the viral neuraminidase. Specifically, we first observed aggre-
gated viral particles on the surface of cells, reminiscent of
previous reports by other investigators studying NA inhibitors or
NA-defective viruses [29,30]. This observation led us to conduct
a cell-free NA assay, revealing that ATA substantially inhibited
the enzymatic activities of both viral and recombinant NA. The
difference in the magnitude of inhibition between H1N1 (PR8
and NC) and H3N2 (NY) viruses in infected cultures (Fig.1 and
Fig. 4) is not fully understood. Interestingly, no marked
differences were observed in the neuraminidase inhibition tests,
i.e. the IC50 between the three strains (Fig. 9A). The reasons for
the discrepancies between tissue culture studies and in vitro
enzymatic studies are still unclear. It is plausible that the in vitro
enzymatic studies may not accurately reflect the events in live
cell cultures. Moreover, the IC50 in the oseltamivir-resistant
strain (H274Y) only increased by 9-fold (Fig. 10B). We think that
ATA is still a potent inhibitor for the oseltamivir-resistant strain
when compared with oseltamivir in inhibiting the H274Y
mutant, for which an over 700- fold increase of IC50 is needed
[33]. It would be interesting to investigate potential ATA
resistant mutants with respect to NA amino acids mutations.
During the preparation of this manuscript, we noted that
Hung et al. [45] also reported that ATA protects cells from a
variety of virus strains in vitro and can inhibit NA in cell-free
assays. In our studies, the IC50 and selective index are higher
than those reported by Hung et al. [45], but we suspect that
such discrepancies might be due to differences in experimental
conditions. While our two groups have demonstrated that viral
NA activity is compromised by ATA, it is possible that ATA
also targets other viral or cellular proteins to exert its anti-
influenza activity. Additional studies are required to answer
this question.
Since inhibition of influenza by ATA and AH is mediated by two
distinct mechanisms, it is not surprising that we observed additive
effects upon simultaneous treatment with both compounds.
Recently the Advisory Committee on Immunization Practices
(ACIP) recommended against the use of amantadine or rimantidine
to treat influenza infection [34] due to increasing evolution of M2
blocker-resistant influenza strains [14,15]. Although influenza
strains resistant to NA inhibitors are less prevalent [5], resistance
to oseltamivir has also been reported [15,46]. This suggests that the
use of a single class of antiviral may have limited protective value
and future influenza treatment strategies will likely include
combinations of medications. Notably, combined used of both
M2 blockers and NA inhibitors does provide additive protection
against influenza infection compared to either treatment alone
[26,47]. Mice infected with 50% lethal doses of either amantadine-
sensitive or amantadine-resistant H5N1 influenza, were more
protected by co-treatment with amantadine and oseltamivir than
those treated with one drug only [47]. We found that simultaneous
treatment with ATA and AH significantly protected MDCK cells
from influenza and dramatically reduced the abundance of
influenza particles released in the medium.
The toxicity of ATA will need to be evaluated further in
animals. In this study, we showed that ATA is associated with
relatively low toxicity in tissue cultures, with the SI being
around 88.8. Although in vivo toxicity studies of ATA are rather
limited, previous research in hamsters has shown that infusion
of ATA was well tolerated in a dose of up to 1 mg/kg/hour for 2
weeks [48]. Also, Jan Balzarini et al. [20] have found that a
Figure 10. ATA inhibits H274Y oseltamivir-resistant virus. (A) ATA inactivates influenza WSN and H274Y viruses. Influenza WSN and H274Y
viruses were pre-incubated with ATA (0, 50, 100 mg/ml) for 30 min, then the virus-ATA mixture was transferred to confluent cell monolayers in 6-well
plates, incubated at 37uC for 2 h and subjected to plaque assay. (B) ATA inhibits enzymatic activity of NA derived from WSN and H274Y viruses. WSN
(N) and H274Y (&) viruses were incubated with increasing concentrations of ATA and NA enzymatic activity was determined by a chemiluminescent
assay. Samples were tested in quadruplicates and presented as means and standard deviations (error bars).
doi:10.1371/journal.pone.0008350.g010
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with LD50 and that mice had a median life span of 18 days upon
intra-peritoneal administration of 31 mg/kg/day. Intra-trache-
al inhalation showed that single doses of ATA as high as 4 mg/
kg were tolerated well in mice [49,50]. However, the
therapeutic and toxic doses would have to be determined in
animal studies, which are currently under investigation in our
laboratory.
In short, ATA is an NA inhibitor that may prove to be a
valuable inclusion to the current arsenal of anti-influenza agents.
The data presented here provide compelling evidence to further
study the anti-influenza potential of ATA in animal models.
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